FX Matters – Tumultuous month; GBP down 3.2%, RMB down 1.3% | Article – HSBC VisionGo

March Highlights
Finance  ·    ·  7 mins read

March was a tumultuous month for financial markets. As the coronavirus (COVID-19) pandemic spread westward, bringing with it lockdowns for many countries, "risk-off" sentiment surged. Policy makers across the globe scrambled to mitigate the adverse economic impacts of the virus and the shutdowns, with some measures unprecedented in nature. "Safe-haven" currencies outperformed, whilst others sold off in drastic fashion. A collapse in oil prices added fuel to the fire. 

UK: A heavy pound

The GBP depreciated 3.2% against the USD in March. The GBP found itself in the bucket of "risk-on" currencies during a month of extreme "risk-off" sentiment, and had fallen as much as 10.4% by 19 March. During daily briefings, Prime Minister (PM) Boris Johnson asked all cafés, gyms, cinemas, and other non-essential shops to close indefinitely, before asking the public to stay at home. 

The UK was one of the few countries to take quick, coordinated, policy action in response to the virus. On 11 March, the Bank of England (BOE) cut its policy rate by 50bp to 0.25%, the same day the UK Chancellor Rishi Sunak pledged a fiscal stimulus of GBP30bn. The BOE cut rates by another 15bp to 0.10% on 19 March, and announced a GBP200bn increase in corporate and government bond holdings. Chancellor Sunak announced further fiscal measures on 20 March, including 80% of wages to be covered (up to GBP2,500 a month) for businesses disrupted by the virus, as well as an extra GBP7bn in welfare support. Despite the proactive policy measures, it was not enough to prevent the GBP from plummeting amidst extreme "risk-off" sentiment. 

A large fiscal stimulus from the US and increased USD funding from the Fed as well as a partial equity rebound helped the GBP to reverse much of its heavy losses, and it ultimately ended the month down 3.2% against the USD. 

China: Canary in the coalmine

The RMB weakened 1.3% against the USD in March. Being the first to encounter the outbreak and implement lockdown measures, China was one of the first to see a drastic deterioration in its economic data – in what would be a forewarning to the rest of the global economy. On 4 March, Caixin PMI services for February plunged to a record low of 26.5, from 51.8 in January. On 16 March, retail sales (YTD, YoY) contracted by 20.5% in the combined period of January and February, versus the expected 4% contraction. Industrial production for the same period came in at -13.5%, below the -3.0% consensus. On 31 March, the National Bureau of Statistics of China (NBS) PMIs for March did show an expansion from the previous month, but this was more of a sequential effect given the record lows in February. 

Amidst the sobering data, China eased both monetary and fiscal policy during the month. On 13 March, the People’s Bank of China (PBOC) announced it will cut the reserve requirement ratio by 50-100bp for certain banks. Then on 16 March, the Ministry of Finance (MOF) announced it will allow both households and companies affected by COVID-19 to delay payment of taxes, or pay in instalments. USD-CNY remained relatively stable during the first half of the month due to the sequencing effect in Asian currencies; however, USD-CNY rose sharply on 18 and 19 March (by 0.6% and 0.9% respectively), as demand for the USD dominated. 

Disclosure appendix 
Important disclosures 
This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy the securities or other investment products mentioned in it and/or to participate in any trading strategy. Information in this document is general and should not be construed as personal advice, given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on it, consider the appropriateness of the information, having regard to their objectives, financial situation and needs. If necessary, seek professional investment and tax advice.
Certain investment products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. Investors should consult with their HSBC representative regarding the suitability of the investment products mentioned in this document and take into account their specific investment objectives, financial situation or particular needs before making a commitment to purchase investment products. 
The value of and the income produced by the investment products mentioned in this document may fluctuate, so that an investor may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Value and income from investment products may be adversely affected by exchange rates, interest rates, or other factors. Past performance of a particular investment product is not indicative of future results. 
HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments (including derivatives) of companies covered in HSBC Research on a principal or agency basis. 
Whether, or in what time frame, an update of this analysis will be published is not determined in advance. 
Additional disclosures 
1 This report is dated as at 2 April 2020. 
2 All market data included in this report are dated as at close 1 April 2020, unless a different date and/or a specific time of day is indicated in the report. 
3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner. 
4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument. 
This document is prepared by The Hongkong and Shanghai Banking Corporation Limited (‘HBAP’), 1 Queen’s Road Central, Hong Kong. HBAP is incorporated in Hong Kong and is part of the HSBC Group. This document is for general circulation and information purposes only. This document is not prepared with any particular customers or purposes in mind and does not take into account any investment objectives, financial situation or personal circumstances or needs of any particular customer. HBAP has prepared this document based on publicly available information at the time of preparation from sources it believes to be reliable but it has not independently verified such information. The contents of this document are subject to change without notice. 
HBAP is not responsible for any loss, damage or other consequences of any kind that you may incur or suffer as a result of, arising from or relating to your use of or reliance on this document. HBAP gives no guarantee, representation or warranty as to the accuracy, timeliness or completeness of this document. 
This document is not investment advice or recommendation nor is it intended to sell investments or services or solicit purchases or subscriptions for them. You SHOULD NOT use or rely on this document in making any investment decision or decision to buy or sell currency. HBAP is not responsible for such use or reliance by you. You SHOULD consult your professional advisor in your jurisdiction if you have any questions regarding the contents of this document. 
You SHOULD NOT reproduce or further distribute the contents of this document to any person or entity, whether in whole or in part, for any purpose. This document may not be distributed to the US, Canada or Australia or any other jurisdiction where its distribution is unlawful. 
Hong Kong 
In Hong Kong, this document is distributed by HBAP to its customers for general reference only. HBAP is not responsible for any loss, damage or other consequences of any kind that you may incur or suffer as a result of, arising from or relating to your use or reliance of this document. HBAP gives no guarantee, representation or warranty as to the accuracy, timeliness or completeness of this document. 
Notwithstanding this document is not investment advice, please be aware of the following for the sake of completeness. Past performance is not an indication of future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. When an investment is denominated in a currency other than the local currency of an investor, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. Where there is no recognised market for an investment, it may be difficult for an investor to sell the investment or to obtain reliable information about its value or the extent of the risk associated with it. 
This document contains forward-looking statements which are, by their nature, subject to significant risks and uncertainties. Such statements are projections, do not represent any one investment and are used for illustration purpose only. Customers are reminded that there can be no assurance that economic conditions described herein will remain in the future. Actual results may differ materially from the forecasts/estimates. No assurance is given that those expectations reflected in those forward-looking statements will prove to have been correct or come to fruition, and you are cautioned not to place undue reliance on such statements. No obligation is undertaken to publicly update or revise any forward-looking statements contained in this document or any other related document whether as a result of new information, future events or otherwise. 
The Hongkong and Shanghai Banking Corporation Limited, its affiliates and associates and their respective officers and/or employees, may have interests in any products referred to in this document by acting in various roles including as distributor, holder of principal positions, adviser or lender. The Hongkong and Shanghai Banking Corporation Limited, its affiliates and associates, and their respective officers and employees, may receive fees, brokerage or commissions for acting in those capacities. In addition, The Hongkong and Shanghai Banking Corporation Limited, its affiliates and associates, and their respective officers and/or employees, may buy or sell products as principal or agent and may effect transactions which are not consistent with the information set out in this document. 
© Copyright 2020. The Hongkong and Shanghai Banking Corporation Limited, ALL RIGHTS RESERVED. No part of this document may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of The Hongkong and Shanghai Banking Corporation Limited.